October 22, 2021 Acad, Gov/Utilities Bio/Pharma/CRO Clinical Research/Diagn. PR/Corporate

Roche’s VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq® (atezolizumab)

Lung cancer remains the leading cause of cancer-related deaths worldwide, with more than 2.2 million people diagnosed globally last year.1 The VENTANA PD-L1 (SP263) Assay helps determine which non-small cell lung cancer patients may benefit from treatment with Tecentriq immunotherapy based on the results of the Phase III IMpower010 study. This new test expands Roche’s... Read more

October 21, 2021 Clinical Research/Diagn. Licensing, IP, and Legal

Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

SANTA CLARA, Calif., October 21, 2021  Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers. Gastric (stomach) cancer is the fifth most common cancer and... Read more

October 21, 2021 Licensing, IP, and Legal M&A, Partnerships

Xylem Expands Partnership with Imagine H2O to Support Water Innovation Entrepreneurs

Global Partnership Scales Imagine H2O’s Work with Entrepreneurial Water Solutions RYE BROOK, N.Y.–(BUSINESS WIRE)–Oct. 21, 2021– Xylem Inc. (NYSE: XYL), a leading global water technology company dedicated to solving the world’s greatest water challenges has announced an expanded commitment to Imagine H2O, the leading water innovation accelerator and ecosystem for water entrepreneurs. As a global... Read more

October 21, 2021 Environ, Ag./Food & Bev Lab Top-10 PAI Top-10 PR/Corporate

Danaher Reports Third Quarter 2021 Results

WASHINGTON, Oct. 21, 2021 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the third quarter 2021.  All results in this release reflect only continuing operations unless otherwise noted. For the quarter ended October 1, 2021, net earnings were $1.2 billion, or $1.54 per diluted common share which represents a 33.0% year-over-year increase... Read more

October 20, 2021 Informatics & Software Microscopy Product Launch

Olympus Announces New Cloud Solution to Streamline Life Science Research

A central hub for research data enables greater productivity at universities and labs October 20, 2021 Olympus is proud to start offering the Olympus Life Science Solution Cloud (OLSC) in Japan to streamline life science research at universities and laboratories. The OLSC provides researchers with a central hub to store and access data—including images, notes... Read more

October 20, 2021 Bio/Pharma/CRO M&A, Partnerships

Waters and University of Delaware Announce Bioprocessing Innovation Partnership, Plan 2022 Opening of Immerse Delaware Lab

Partnership will focus on developing analytical solutions to better characterize bioprocesses towards improved quality, yields and efficiency News Summary: Waters and University of Delaware announce a multi-year collaboration to develop technology for analytical characterization of manufacturing processes for biologics and novel modalities. Waters’ staff and university researchers will co-locate at Immerse™ Delaware, an Innovation and... Read more

October 19, 2021 Liq. Handling & Robotics Product Launch

Unchained Labs blasts Big Kahuna and Junior into the future, launches LEA 10!

October 19, 2021 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics and gene therapy researchers the right tools for the job, released its LEA 10 automation software today – making Big Kahuna and Junior even more ready to plow through scientific challenges and workflow bottlenecks. Big Kahuna and Junior are workhorses that labs rely... Read more

October 19, 2021 PR/Corporate

Pacific Biosciences of California, Inc. Third Quarter 2021 Financial Results Call

MENLO PARK, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its third quarter 2021 financial results on Tuesday, November 2, 2021, at 4:30pm Eastern Time. The call will be webcast and may be accessed at Pacific Biosciences’ website at: https://investor.pacificbiosciences.com/. Date:... Read more